Douglas J. Manion - 01 Jan 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Pres and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Jan 2024
Net transactions value: -$9,581
Form type: 4
Filing time: 03 Jan 2024, 16:44:56 UTC
Previous filing: 03 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+27,000	+113%		50,938	01 Jan 2024	Direct	F1
transaction	ACRS	Common Stock	Tax liability	$9,581	-9,125	-18%	$1.05	41,813	01 Jan 2024	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-27,000	-25%	$0.000000	81,000	01 Jan 2024	Common Stock	27,000		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	On February 1, 2023, the Reporting Person was granted 108,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.